At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 62 enrolled
Drug / intervention
Secukinumab +1 moredrug
Likely dose
Secukinumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, 24-week Study Investigating the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Moderate to Severe Rotator Cuff Tendinopathy and Failure to Conventional Therapy
In Brief
A Phase 3 clinical trial evaluating Secukinumab and Placebo for Tendinopathy. Completed, enrolled 62 participants across 19 sites.
Detailed Summary
The purpose of this study was to investigate the efficacy and safety of secukinumab subcutaneously (s.c.) compared to placebo in adult patients with moderate to severe rotator cuff tendinopathy and failure to conventional therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTendinopathy
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartDec 2022
Primary CompletionDec 2024
TodayJul 2026
First PostedOct 6, 2022
Enrollment StartDec 2, 2022
Primary CompletionDec 18, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.7 years ago
Interventions
Secukinumabdrug
Secukinumab 300 mg s.c for 12 weeks in a pre-filled syringe (PFS)
Placeboother
Placebo to match secukinumab s.c. for 12 weeks in a PFS